Keywords: tysabri, shows, strong, results, add-on, ms, therapy

Tysabri shows strong results as add-on MS therapy

Article | 25 April 2005

Print This

US biotechnology group Biogen Idec and Northern Ireland-based drugmaker Elan have reported positive data from their Phase III SENTINEL trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in